home / stock / lixt / lixt news

LIXT News and Press, Lixte Biotechnology Holdings Inc. From 04/30/20

Stock Information
Company Name: Lixte Biotechnology Holdings Inc.
Stock Symbol: LIXT
Market: OTC
Website: lixte.com
Menu
LIXT LIXT Quote LIXT Short LIXT News LIXT Articles LIXT Message Board
Get LIXT Alerts

News, Short Squeeze, Breakout and More Instantly...
LIXT - Lixte Biotechnology's PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors

EAST SETAUKET, NY, April 30, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( OTCQB: LIXT ) noted that investigators at the National Cancer Institute (NCI) and National Institute of Neurological Disorders and Stroke (NINDS) reported that Lixte’s lead clinical compound,...
LIXT - First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology's LB-100 to Enter Recurrent Malignant Brain Tumors

EAST SETAUKET, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( OTCQB: LIXT ) announced that the National Cancer Institute (NCI) has enrolled the first two patients of a planned eight patient pharmacologic study of the ability of its lead compound, LB-100, to ent...

LIXT - The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings’ LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas

EAST SETAUKET, N.Y., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( OTCQB: LIXT ) announced that it signed a clinical trial agreement with the Spanish Sarcoma Group (Grupo Español de Investigación en Sarcomas, GEIS) to support a Phase 1b/randomized Phase 2...

LIXT - First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology's LB-100 in Low or Intermediate-1 Risk Myelodysplastic Syndrome

EAST SETAUKET, NY, July 18, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the first patient has been enrolled in its Phase 1b/2 study of the safety and therapeutic benefit of Lixte’s lead clinical compound, LB-100, in patients with low a...
LIXT - Lixte Biotechnology's PP2A Inhibitor, LB-100, Improves Brain Function and Motor Impairment in a Mouse Model of Angelman Syndrome, a Rare Human Neurodevelopmental Disorder

EAST SETAUKET, NY, June 25, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( OTCQB: LIXT ) noted that a group of neuroscientists in China and Japan reported that Lixte’s lead clinical compound, LB-100, improved muscle strength, movement coordination and learning in a m...

LIXT - Lixte Biotechnology's LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100's Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors

EAST SETAUKET, NY, May 15, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( OTCQB: LIXT ) announced the opening of a pharmacologic study of the ability of its lead clinical compound, LB-100, to enter the brain and penetrate recurrent glioblastoma multiforme tumors in patients...

Previous 10 Next 10